Immix Biopharma initiated with an Outperform at Citizens

Citizens initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $23 price target The firm says the company’s NXC-201 has demonstrated “compelling” clinical data in terms of response rates and durability of response, resulting in disease modification for patients with AL amyloidosis. Citizens believes Immix shares represent an attractive investment opportunity, with 41% potential downside in a bear case and 415% potential upside in a bull case.